• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Tempus AI Inc.

    5/9/25 4:18:56 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001642853
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Tempus AI, Inc.
    SEC File Number
    001-42130
    Address of Issuer
    600 WEST CHICAGO AVENUE
    SUITE 510
    CHICAGO
    ILLINOIS
    60654
    Phone
    800-976-5448
    Name of Person for Whose Account the Securities are To Be Sold
    REVOLUTION GROWTH III, LP
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Shareholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A Common
    Merrill Lynch Pierce Fenner and Smith
    One Bryant Park
    New York � NY � 10036
    77050219.4016807245605/09/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A Common09/18/2017Private PlacementIssuerCheckbox not checked77009/18/2017Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/09/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Kate Wilschutz

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    10/2/2024$45.00 → $60.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tempus Reports First Quarter 2025 Results

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

      5/6/25 4:01:00 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • AI Healthcare Boom Gains Speed as Regulators and Innovators Align

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion. Behind the scenes, several new AI healthcare tech developments are taking place, with updates rec

      5/5/25 12:35:00 PM ET
      $GEHC
      $SDGR
      $TEM
      $TVGN
      Medical Electronics
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Programming Data Processing
    • Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records. Notetaker complements Tempus' existing mental health platform designed to support clinicians in delivering personalized care. It joins other precision medicine solutions, including the Tempus nP pharmacogenomic test and PRO™, the company's patient reported

      5/5/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Reporting)

      8/20/24 4:17:55 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Tempus AI with a new price target

      BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

      4/21/25 8:39:11 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by Analyst with a new price target

      Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

      2/25/25 7:14:46 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by William Blair

      William Blair downgraded Tempus AI from Outperform to Mkt Perform

      2/12/25 7:11:34 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    SEC Filings

    See more
    • SEC Form 144 filed by Tempus AI Inc.

      144 - Tempus AI, Inc. (0001717115) (Subject)

      5/9/25 4:18:56 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tempus AI Inc.

      SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)

      5/9/25 4:14:44 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 424B3 filed by Tempus AI Inc.

      424B3 - Tempus AI, Inc. (0001717115) (Filer)

      5/6/25 4:12:24 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Financials

    Live finance-specific insights

    See more
    • Tempus Reports First Quarter 2025 Results

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

      5/6/25 4:01:00 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report First Quarter 2025 Financial Results on May 6

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

      4/24/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i

      2/11/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 5:00:02 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 4:30:28 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

      SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

      8/20/24 4:27:51 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Fukushima Ryan sold $1,047,239 worth of shares (20,000 units at $52.36), decreasing direct ownership by 2% to 884,460 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/8/25 4:30:06 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director Epstein David R sold $19,795 worth of shares (370 units at $53.50), decreasing direct ownership by 1% to 25,914 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/5/25 4:15:22 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Chief Financial Officer Rogers James William was granted 4,372 shares, increasing direct ownership by 3% to 169,122 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      5/2/25 6:45:12 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology